The UK company is the latest to join ranks of AI-focused drugmakers attracting venture capital.

The researcher who invented Viagra and a colleague at Cambridge University have become the latest to join the ranks of drug developers using artificial intelligence and attracting attention from venture capitalists.

Cambridge, UK-based Healx said Thursday that it had raised $10 million in a Series A funding round, led by London-based venture capital firm Balderton Capital. Fellow British venture capital firm Amadeus Capital Partners and Jonathan Milner – founder of life sciences supplier Abcam – also participated. Cambridge Rare Diseases Network founder Tim Guilliams and David Brown – who invented Pfizer’s erectile dysfunction drug, which is now available as a generic – are the founders of Healx.

The company uses the HealNet database, which maps more than 1 billion disease, patient and drug interactions and was built and maintained using machine learning techniques. The company plans to use the Series A round to expand its team of software engineers, data scientists, pharmacologists and drug development researchers.

Read more at medcitynews.com

Image Credit:  Alias Studio Sydney

News This Week

Stem Cell Membrane-Coated Nanoparticles in Tumor Therapy

Cell membrane-coated nanoparticles, applied in targeted drug delivery strategies, combine the intrinsic advantages of synthetic nanoparticles and cell membranes. Although stem cell-based delivery systems were highlighted for their targeting capability in tumor therapy, inappropriate [...]

Self-Healable, Human-Like Artificial Skin

Self-healable ionic sensing materials with fatigue resistance are imperative in robotics and soft electronics for extended service life. The existing artificial ionic skins with self-healing capacity were prepared by network reconfiguration, constituting low-energy amorphous [...]